BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/24/2020 12:21:39 PM | Browse: 587 | Download: 1265
 |
Received |
|
2020-04-17 02:39 |
|
Peer-Review Started |
|
2020-04-17 02:40 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-27 07:13 |
|
Revised |
|
2020-05-27 15:36 |
|
Second Decision |
|
2020-06-11 09:24 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-06-12 00:25 |
|
Articles in Press |
|
2020-06-12 00:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-06-26 13:26 |
|
Typeset the Manuscript |
|
2020-07-21 02:42 |
|
Publish the Manuscript Online |
|
2020-07-24 12:21 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical and Translational Research |
| Article Title |
Identification of APEX2 as an oncogene in liver cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ru Zheng, Heng-Liang Zhu, Bing-Ren Hu, Xiao-Jiao Ruan and Hua-Jie Cai |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Wenzhou Science and Technology Bureau |
Y20180147 |
|
| Corresponding Author |
Hua-Jie Cai, MD, Associate Chief Physician, Department of General Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Ouhai District, Wenzhou 325000, Zhejiang Province, China. huajie.cai@outlook.com |
| Key Words |
APEX2; High expression; Worse prognosis; Pro-oncogenic pathway; Oncogene; Liver cancer |
| Core Tip |
In this study, we identify that APEX2 is highly expressed in liver hepatocellular carcinoma (LIHC), and the overexpression of APEX2 could act as a worse prognostic factor. The GO Ontology based GSEA analysis shows APEX2 is an important regulator in the kinetochore and spindle microtubule. And APEX2 is also closely associated with the biological processes of chromosome segregation and DNA replication. The molecular mechanism analysis indicates APEX2 is positively associated with cell cycle and MYC pathways. Knockdown of APEX2 can suppress the cell viability of liver cancer cells, and inhibit CCNB1 and MYC pathways, these results indicate APEX2 is an oncogene in LIHC. |
| Publish Date |
2020-07-24 12:21 |
| Citation |
Zheng R, Zhu HL, Hu BR, Ruan XJ, Cai HJ. Identification of APEX2 as an oncogene in liver cancer. World J Clin Cases 2020; 8(14): 2917-2929 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i14/2917.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i14.2917 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
